Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Department of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China.
J Nanobiotechnology. 2021 Jan 6;19(1):8. doi: 10.1186/s12951-020-00738-8.
Non-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibody targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells.
Accordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called CCM@MSNs-ISOIM. The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis.
Furthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.
非霍奇金淋巴瘤(NHL)在细胞遗传学、免疫表型和临床特征上具有巨大的异质性,化疗目前仍是主要的治疗方式。虽然采用单克隆抗体靶向药物显著提高了整体疗效,但仍有各种患者面临耐药或复发的问题。中药在恶性肿瘤的治疗中已有悠久的应用历史。因此,我们构建了一种基于细胞膜修饰的载中药介孔硅纳米粒子的低 pH 值敏感性药物递送系统,可降低全身毒性并提高肿瘤细胞靶向药物递送的治疗效果。
因此,本研究提出构建一种基于载中药欧前胡素的介孔硅纳米粒子(MSNs)的纳米平台,该纳米平台被称为 CCM@MSNs-ISOIM 的癌细胞膜(CCM)伪装。所提出的纳米平台具有免疫逃逸、抗吞噬、高载药率、低 pH 值敏感性、良好的生物相容性和肿瘤部位的主动靶向性,可以阻断淋巴瘤细胞周期并促进线粒体介导的细胞凋亡。
此外,本研究为寻找淋巴瘤的新型临床治疗方法提供了理论依据。